Active Not RecruitingNCT06941844
Study of MM120 for Major Depressive Disorder (Emerge)
This study is active but not recruiting in the United States. It focuses on depression.
DepressionOtherFrom 18 Years to 74 Years
Study directory
Back to overviewMental health studies with practical context.
Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.
OngoingEUCTR 2022-001515-10
Safety and Efficacy of KarXT for Schizophrenia
This study is ongoing in France, in Spain, in Slovakia, .... It is testing Safety and Efficacy of KarXT for Schizophrenia.
SchizophreniaOther
CompletedEUCTR 2019-003343-29
Pimavanserin for schizophrenia
This study is completed in Czech Republic, in Poland, in Hungary, .... It is testing pimavanserin for schizophrenia.
SchizophreniaOther
OngoingEUCTR 2018-000821-29
2-part Study Composed of a 1-Year Active-comparator, Dose-optimization Evaluation followed by a 1-Year Open-lab...
This study is ongoing in the United Kingdom, in Belgium, in Germany, .... It focuses on ADHD.
ADHDOther
Enrolling By InvitationNCT07521683
NS-136 for schizophrenia
This study is enrolling by invitation in China. It is testing NS-136 for schizophrenia.
SchizophreniaOtherFrom 18 Years to 65 Years
OngoingEUCTR 2016-004973-42
Efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period for Schizophrenia
This study is ongoing in the United Kingdom and in View results. It is testing efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period for Schizophrenia.
SchizophreniaOther
OngoingEUCTR 2018-002740-82
A phase II double-blinded, parallel group study to examine the efficacy and safety of BI 425809 once daily with adjunctive Computerized Cognitive Training over 12 wee...
This study is ongoing in the United Kingdom and in View results. It focuses on Schizophrenia.
SchizophreniaOther
CompletedNCT01886469
A Phase II, Adaptive study Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)
This study is completed in Canada. It focuses on ADHD.
ADHDOtherFrom 6 Years to 17 Years
Active Not RecruitingNCT05733546
A Phase II, Multicentre, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in people with Recurrent Major Depressive Disorder
This study is active but not recruiting in the United States. It focuses on depression.
DepressionDrugA study involving a medication or substance.Over 18 Years
CompletedEUCTR 2020-006062-36
A PHASE II/III, PROSPECTIVE, MULTI-CENTER, 4-WEEK, STUDY, DESIGNED TO DETERMINE THE SAFETY, TOLERABILITY, EEG EFFECTS AND EFFICACY OF ORAL DOSES OF 30 M...
This study is completed in Germany, in Italy, in Czech Republic, .... It focuses on Schizophrenia.
SchizophreniaOther
CompletedNCT01614899
A Phase III Study of SM-13496 (Lurasidone HCl) in people with Schizophrenia
This study is completed. It focuses on schizophrenia and currently lists study information in Japan, Malaysia, South Korea, and Taiwan.
SchizophreniaOtherFrom 18 Years to 74 Years
CompletedNCT01986101
A Phase III Study of SM-13496 in people with Bipolar I Depression.
This study is completed. It focuses on bipolarity and currently lists study information in Japan, Lithuania, Malaysia, the Philippines, Russian Federation, Slovakia, Taiwan, and Ukraine.
Bipolarity, DepressionOtherFrom 18 Years to 74 Years